SLX4

SLX4 structure-specific endonuclease subunit, the group of BTB domain containing|FA complementation groups

Basic information

Region (hg38): 16:3581181-3611606

Previous symbols: [ "BTBD12" ]

Links

ENSG00000188827NCBI:84464OMIM:613278HGNC:23845Uniprot:Q8IY92AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • Fanconi anemia complementation group P (Definitive), mode of inheritance: AR
  • Fanconi anemia (Supportive), mode of inheritance: AR
  • Fanconi anemia complementation group P (Strong), mode of inheritance: AR
  • familial ovarian cancer (No Known Disease Relationship), mode of inheritance: AD
  • hereditary breast carcinoma (Refuted Evidence), mode of inheritance: AD
  • Fanconi anemia complementation group P (Definitive), mode of inheritance: AR

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Fanconi anemia, complementation group PARAllergy/Immunology/Infectious; Cardiovascular; Hematologic; OncologicSpecific treatments can help manifestations (eg, oral androgens for blood counts; G-CSF for neutrophil count); HSCT can be curative, but solid tumor risk may remain; Surveillance for complications such as bone marrow failure is recommended; Fanconi anemia can involve congenital cardiac (and other) anomalies, and awareness may allow early managementAudiologic/Otolaryngologic; Allergy/Immunology/Infectious; Cardiovascular; Dermatologic; Gastrointestinal; Hematologic; Musculoskeletal; Neurologic; Oncologic; Ophthalmologic; Renal21240275; 21240277; 20301575

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the SLX4 gene.

  • Fanconi anemia (65 variants)
  • not provided (4 variants)
  • Fanconi anemia complementation group P (3 variants)
  • Fanconi anemia complementation group A (2 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the SLX4 gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
17
clinvar
512
clinvar
14
clinvar
543
missense
1079
clinvar
26
clinvar
13
clinvar
1118
nonsense
29
clinvar
12
clinvar
3
clinvar
44
start loss
0
frameshift
41
clinvar
13
clinvar
1
clinvar
55
inframe indel
31
clinvar
1
clinvar
32
splice donor/acceptor (+/-2bp)
11
clinvar
11
splice region
27
19
1
47
non coding
45
clinvar
91
clinvar
44
clinvar
180
Total 70 36 1176 630 71

Highest pathogenic variant AF is 0.0000197

Variants in SLX4

This is a list of pathogenic ClinVar variants found in the SLX4 region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
16-3581192-C-G Fanconi anemia complementation group P Uncertain significance (Jan 13, 2018)319121
16-3581247-C-T Fanconi anemia complementation group P Benign (Jan 12, 2018)319122
16-3581295-C-T Fanconi anemia complementation group P Uncertain significance (Jan 12, 2018)888238
16-3581301-T-C Fanconi anemia complementation group P Likely benign (Jan 13, 2018)888239
16-3581307-T-C Fanconi anemia complementation group P Likely benign (Jan 13, 2018)885126
16-3581320-T-C Fanconi anemia complementation group P Benign (Jan 12, 2018)319123
16-3581338-T-C Fanconi anemia complementation group P Benign (Jan 12, 2018)319124
16-3581358-G-A Fanconi anemia complementation group P Benign (Jan 12, 2018)319125
16-3581385-G-A Fanconi anemia complementation group P Uncertain significance (Jan 13, 2018)319126
16-3581398-T-C Fanconi anemia complementation group P Uncertain significance (Jan 13, 2018)885127
16-3581455-G-A Fanconi anemia complementation group P Uncertain significance (Jan 12, 2018)885128
16-3581460-G-A Fanconi anemia complementation group P Uncertain significance (Jan 13, 2018)885129
16-3581471-T-C Fanconi anemia complementation group P Uncertain significance (Jan 12, 2018)319127
16-3581531-C-G Fanconi anemia complementation group P Uncertain significance (Jan 12, 2018)319128
16-3581535-C-T Fanconi anemia complementation group P Benign (Jan 13, 2018)319129
16-3581621-A-G Fanconi anemia complementation group P Benign (Jan 13, 2018)319130
16-3581684-A-G Fanconi anemia complementation group P Likely benign (Jan 13, 2018)319131
16-3581687-C-T Fanconi anemia complementation group P Benign (Jan 12, 2018)319132
16-3581690-T-C Fanconi anemia complementation group P Uncertain significance (Jan 13, 2018)319133
16-3581764-C-T Fanconi anemia complementation group P Uncertain significance (Jan 13, 2018)886038
16-3581787-G-A Fanconi anemia complementation group P Benign (Jan 12, 2018)319134
16-3581849-C-A Fanconi anemia complementation group P Uncertain significance (Jan 13, 2018)887032
16-3581873-T-A Fanconi anemia complementation group P Uncertain significance (Jan 13, 2018)319135
16-3581968-G-A Fanconi anemia complementation group P Uncertain significance (Jan 13, 2018)319136
16-3582031-C-T Fanconi anemia complementation group P Uncertain significance (Jan 13, 2018)319137

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
SLX4protein_codingprotein_codingENST00000294008 1430418
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
1.57e-220.84612559101571257480.000624
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense-1.8812241.05e+31.160.000070211861
Missense in Polyphen296270.991.09233358
Synonymous-4.095774651.240.00003563821
Loss of Function2.414566.20.6800.00000369767

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0006510.000650
Ashkenazi Jewish0.000.00
East Asian0.001320.00131
Finnish0.0003720.000370
European (Non-Finnish)0.0007090.000695
Middle Eastern0.001320.00131
South Asian0.0008520.000817
Other0.0003260.000326

dbNSFP

Source: dbNSFP

Function
FUNCTION: Regulatory subunit that interacts with and increases the activity of different structure-specific endonucleases. Has several distinct roles in protecting genome stability by resolving diverse forms of deleterious DNA structures originating from replication and recombination intermediates and from DNA damage. Component of the SLX1-SLX4 structure-specific endonuclease that resolves DNA secondary structures generated during DNA repair and recombination. Has endonuclease activity towards branched DNA substrates, introducing single-strand cuts in duplex DNA close to junctions with ss-DNA. Has a preference for 5'-flap structures, and promotes symmetrical cleavage of static and migrating Holliday junctions (HJs). Resolves HJs by generating two pairs of ligatable, nicked duplex products. Interacts with the structure- specific ERCC4-ERCC1 endonuclease and promotes the cleavage of bubble structures. Interacts with the structure-specific MUS81- EME1 endonuclease and promotes the cleavage of 3'-flap and replication fork-like structures. SLX4 is required for recovery from alkylation-induced DNA damage and is involved in the resolution of DNA double-strand breaks. {ECO:0000269|PubMed:19595721, ECO:0000269|PubMed:19595722, ECO:0000269|PubMed:19596235, ECO:0000269|PubMed:19596236}.;
Disease
DISEASE: Fanconi anemia complementation group P (FANCP) [MIM:613951]: A disorder affecting all bone marrow elements and resulting in anemia, leukopenia and thrombopenia. It is associated with cardiac, renal and limb malformations, dermal pigmentary changes, and a predisposition to the development of malignancies. At the cellular level it is associated with hypersensitivity to DNA-damaging agents, chromosomal instability (increased chromosome breakage) and defective DNA repair. Some individuals affected by Fanconi anemia of complementation group P have skeletal anomalies. {ECO:0000269|PubMed:21240275, ECO:0000269|PubMed:21240277}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
Fanconi anemia pathway - Homo sapiens (human);HDR through Homologous Recombination (HR) or Single Strand Annealing (SSA);Fanconi Anemia Pathway;DNA Repair;DNA Double-Strand Break Repair;Homology Directed Repair;Resolution of D-loop Structures through Holliday Junction Intermediates;Resolution of D-Loop Structures;HDR through Homologous Recombination (HRR) (Consensus)

Intolerance Scores

loftool
rvis_EVS
1.17
rvis_percentile_EVS
92.73

Haploinsufficiency Scores

pHI
0.0621
hipred
Y
hipred_score
0.568
ghis
0.547

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
S
essential_gene_gene_trap
E
gene_indispensability_pred
N
gene_indispensability_score
0.114

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumHigh
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Slx4
Phenotype
growth/size/body region phenotype; endocrine/exocrine gland phenotype; craniofacial phenotype; cellular phenotype; homeostasis/metabolism phenotype; immune system phenotype; skeleton phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); reproductive system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); limbs/digits/tail phenotype; vision/eye phenotype;

Zebrafish Information Network

Gene name
slx4
Affected structure
intrahepatic bile duct
Phenotype tag
abnormal
Phenotype quality
absent

Gene ontology

Biological process
meiotic DNA double-strand break processing;resolution of meiotic recombination intermediates;double-strand break repair via homologous recombination;DNA replication;DNA repair;nucleotide-excision repair;DNA double-strand break processing involved in repair via single-strand annealing;interstrand cross-link repair;positive regulation of catalytic activity;telomeric D-loop disassembly;response to intra-S DNA damage checkpoint signaling;t-circle formation;negative regulation of telomere maintenance via telomere lengthening;positive regulation of t-circle formation
Cellular component
chromosome, telomeric region;nuclear chromosome, telomeric region;nuclear chromatin;nucleoplasm;cytosol;cell junction;Slx1-Slx4 complex;Holliday junction resolvase complex;ERCC4-ERCC1 complex
Molecular function
endodeoxyribonuclease activity;protein binding;enzyme activator activity;crossover junction endodeoxyribonuclease activity;5'-flap endonuclease activity;3'-flap endonuclease activity